Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Denali Therapeutics Inc. (DNLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 144 Form 144 - Report of proposed sale of securities:
10/05/2023 144 Form 144 - Report of proposed sale of securities:
08/23/2023 144 Form 144 - Report of proposed sale of securities:
08/23/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights"
07/18/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
06/28/2023 144 Form 144 - Report of proposed sale of securities:
06/16/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights"
04/20/2023 144 Form 144 - Report of proposed sale of securities:
04/18/2023 ARS Form ARS - Annual Report to Security Holders:
04/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/18/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/30/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/27/2023 8-K Quarterly results
Docs: "Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 7.3% stake in Denali Therapeutics Inc.
02/09/2023 SC 13G/A FMR LLC reports a 4.3% stake in DENALI THERAPEUTICS INC
01/20/2023 SC 13G/A BAILLIE GIFFORD & CO reports a 11.1% stake in Denali Therapeutics Inc
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy